-
Hydroxychloroquine and azithromycin effective in treating coronavirus: French study

A combination of hydroxychloroquine and azithromycin has been found effective in treating patients with the COVID-19 coronavirus, according to a study conducted by French researchers on 80 cases who recovered from the virus within six days of treatment. French study
The study was conducted by a team led by Didier Raoult of the IHU-Mediterranee Infection in France.
Out of the 80 patients who received a combination of hydroxychloroquine and azithromycin, Raoult and his team found a clinical improvement in all but one patient, 86, who died. One 74-year-old patient was still in the ICU at the time the study was published.
Hydroxychloroquine is an antimalarial and anti-inflammatory used to treat auto-immune disorders such as lupus and rheumatoid arthritis, but it has been tried with some success against symptoms of the novel coronavirus.
Regionally, Bahrain is one of the first countries to test hydroxychloroquine as a treatment for COVID-19, having first used the drug on February 26, two days after registering its first case of the coronavirus.
Around the world, countries are expanding access to hydroxychloroquine and chloroquine, related compounds that are synthetic forms of quinine, which come from cinchona trees and have been used for centuries to treat malaria.
“We confirm the efficacy of hydroxychloroquine associated with azithromycin in the treatment of COVID-19 and its potential effectiveness in the early impairment of contagiousness,” the French researchers said in their study’s conclusion.
“Given the urgent therapeutic need to manage this disease with effective and safe drugs and given the negligible cost of both hydroxychloroquine and azithromycin, we believe that other teams should urgently evaluate this therapeutic strategy both to avoid the spread of the disease and to treat patients before severe irreversible respiratory complications take hold,” the researchers added. French study
There is still debate among medical experts regarding the use of chloroquine as a treatment. The World Health Organization has not approved the use of chloroquine for coronavirus symptomatic treatment. In the United States, the US Food and Drug Administration (FDA) is currently studying a way to make the drug available for emergency use, but in a way that gives the government data about whether it is safe and effective. levant
source: Ismaeel Naar levant
You May Also Like
Popular Posts
Caricature
BENEFIT Sponsors Gulf Uni...
- April 17, 2025
BENEFIT, the Kingdom’s innovator and leading company in Fintech and electronic financial transactions service, has announced its sponsorship of the “Innovation and Sustainable Technology Solutions Competition (GU - IST Solutions), hosted by Gulf University at its main campus.
This strategic sponsorship reflects BENEFIT’s active role in advancing technological innovation and fostering sustainable solutions to future challenges. It also seeks to empower Bahraini youth by enhancing their skills, capabilities, and competitiveness in innovation and solution development—contributing meaningfully to the broader goals of sustainable development across all sectors.
As part of BENEFIT’s active involvement in the competition, the company has announced that Hanan Abdulla Hasan, Senior Manager of Public Relations and Communication, will serve on the competition’s supervisory committee. Her upcoming participation reflects BENEFIT’s forward-looking commitment to championing academic and professional excellence.
Commenting on the occasion, Hanan Abdulla Hasan, Senior Manager of Public Relations and Communication at BENEFIT, said, “We are privileged to support this pioneering initiative, which aligns seamlessly with BENEFIT’s enduring commitment to fostering innovation and nurturing the potential of Bahrain’s youth. Our participation is rooted in a deep sense of social responsibility and a firm belief in the pivotal role of innovation in shaping a sustainable future. Through such platforms, we seek to empower the next generation with the knowledge, skills, and foresight required to develop impactful solutions that address future challenges, in line with the United Nations Sustainable Development Goals 2030.”
Dr. Aseel Al Ayash Dean of the College of Engineering in Gulf University commented, “We extend our sincere gratitude to BENEFIT for their generous sponsorship and support of the Innovation and Sustainable Technology Solutions Competition. This contribution plays an instrumental role in helping us achieve the strategic goals of this initiative, namely, cultivating a culture of innovation and sustainability, encouraging efforts that address the imperatives of sustainable development, and enhancing the practical and professional capabilities of our students and participants.”
The event will bring together a diverse spectrum of participants, including secondary school students, university undergraduates, engineers, industry professionals, entrepreneurs, academic researchers, and subject matter experts representing a wide range of disciplines.
The competition seeks to inspire participants to develop and present innovative, sustainable technologies aimed at addressing pressing environmental, social, and economic challenges. It encourages the formulation of business models that integrate advanced technological solutions with core principles of sustainability. Moreover, it serves as a platform for emerging leaders, entrepreneurs, and innovators to contribute to the advancement of the Sustainable Development Goals, promote the ethos of responsible technology, and demonstrate its transformative potential across various sectors.
Attendees will have the opportunity to view a series of project presentations submitted by participants, covering diverse areas such as eco-friendly product design, smart and sustainable innovations, renewable energy technologies, water conservation and management, waste minimisation and recycling, green architectural solutions, and sustainable transportation systems. Outstanding projects will be formally recognised and awarded at the conclusion of the event.
opinion
Report
ads
Newsletter
Subscribe to our mailing list to get the new updates!